(Q46822929)

25 December 2017

title

Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine (English)

1 reference

25 December 2017

author name string

Dean Johnston

series ordinal

1

1 reference

25 December 2017

Jean-Claude Bystryn

series ordinal

2

1 reference

25 December 2017

language of work or name

English

0 references

publication date

8 November 2005

1 reference

25 December 2017

published in

Vaccine

1 reference

25 December 2017

volume

24

1 reference

25 December 2017

issue

11

1 reference

25 December 2017

page(s)

1958-1965

1 reference

25 December 2017

cites work

Vaccines for melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

Cancer immunotherapy: a treatment for the masses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

Synopsis of the 6th Walker's Cay Colloquium on Cancer Vaccines and Immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

Peptide-based vaccines for cancer immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

Cancer immunotherapy: moving beyond current vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

Immunotherapy of melanoma: the good news, the bad ones and what to do next

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

Advances in the use of dendritic cells and new adjuvants for the development of therapeutic vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

Enhanced priming of antigen-specific CTLs in vivo by embryonic stem cell-derived dendritic cells expressing chemokine along with antigenic protein: application to antitumor vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

Chemokine gene modification of human dendritic cell-based tumor vaccines using a recombinant adenoviral vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

Adjuvant activities of immune response modifier R-848: comparison with CpG ODN

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

The immune response modifier and Toll-like receptor 7 agonist S-27609 selectively induces IL-12 and TNF-alpha production in CD11c+CD11b+CD8- dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

Role of Toll-like receptors in costimulating cytotoxic T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

Molecular mechanisms of B lymphocyte activation by the immune response modifier R-848.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

The immune response modifier resiquimod mimics CD40-induced B cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

Changing paradigms in dermatology: antivirals in dermatology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

Topical immunomodulation in dermatology: potential of toll-like receptor agonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

Introduction of soluble protein into the class I pathway of antigen processing and presentation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

Identification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

Topical imiquimod 5% cream in external anogenital warts: a randomized, double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

Topically applied imiquimod inhibits vascular tumor growth in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

Evaluation of superficial basal cell carcinomas after treatment with imiquimod 5% cream or vehicle for apoptosis and lymphocyte phenotyping

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

Two cases of squamous cell carcinoma treated with topical imiquimod 5%.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

Role of imiquimod in skin cancer treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

Use of imiquimod for treating skin cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

Resiquimod is a modest adjuvant for HIV-1 gag-based genetic immunization in a mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.10.045

10.1016/J.VACCINE.2005.10.045

7 January 2021

Identifiers

DOI

1 reference

25 December 2017

1 reference

25 December 2017